Promising Pipeline and Solid Financials: Analyst's Buy Rating on Aquestive Therapeutics

TipRanksJan 15 15:04 · Ratings

Aquestive Therapeutics Updates on Strategic Goals and Drug Progress

TipRanksJan 13 21:14

Aquestive Therapeutics Outlines 2025 Goals, Including Anaphylm Launch and AQST-108 Phase 2a Trial

BenzingaJan 13 20:50

Express News | Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

BreakingsJan 13 20:00

H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10

Futu NewsDec 21, 2024 02:31 · Ratings

Aquestive Therapeutics Gains Buy Rating Amid Orphan Drug Exclusivity and Promising Product Pipeline

TipRanksDec 21, 2024 02:25 · Ratings